CAMBRIDGE, England, November 20, 2015 /PRNewswire/ --
Inivata Limited, a clinical cancer genomics company focussed on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announces the appointment of Dr James Clark as Vice President of Clinical Laboratory Operations.
To accelerate the development of the Company's patient testing infrastructure, Dr Clark will be responsible for set up and management of Inivata's clinical testing laboratories in the US and Europe. He will also be closely involved with product development and commercialisation.
Dr Clark brings executive management level experience at the nexus of the therapeutic and diagnostic industries, specialising in Companion Diagnostics (CDx) and Next Generation Sequencing (NGS). During his career he has worked extensively in therapeutics and molecular oncology, developing and commercialising over 10 diagnostic products. James brings US-based CLIA lab experience having held executive roles in a number of oncology companies including VP Research and Development at MDx Health and COO at Response Genetics.
Dr Clark has a BSc in Microbiology and obtained his PhD from the Biochemistry Department of Glasgow University.
Inivata CEO Michael Stocum said, "James has an established track record in commercialising new products and services. This, together with his CLIA lab experience, will be invaluable as we drive forward our development and establish the clinical laboratory capabilities that enable us to offer the benefits of our ctDNA testing platform to oncologists and cancer patients to aid in optimising treatment selection."
Dr James Clark said, "I share Inivata's passion for the adoption of a personalised medical approach as part of clinical practice in cancer treatment. Inivata is a recognised leader in ctDNA analysis and I look forward to joining the team at an exciting time for the Company as its non-invasive biopsy products are rolled out and reach patients."
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.
Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient's cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach - a liquid biopsy - offers a revolution in how cancer is detected, monitored and treated.
Inivata is based in Cambridge, UK and its scientific founders are leading figures in the ctDNA field: Nitzan Rosenfeld (Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University College London), James Brenton (Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge Institute, University of Cambridge).
Inivata's investors and shareholders include Imperial Innovations, Johnson & Johnson Innovation - JJDC, Inc., Cambridge Innovation Capital and Cancer Research Technology.
Consilium Strategic Communications
Chris Gardner / Laura Thornton